REMSleep Holdings, Inc. provides an update on its testing protocol for 510K clearance of its DeltaWave CPAP Mask. RemSleep has completed the testing protocol for 510K clearance and all tests have successfully passed including the Cytotoxicity and MLA tests which were the subject of past issues requiring retesting. The company previously provided an estimate of 3-6 weeks for compiling these results and has reduced that estimate to 2-4 weeks before submitting to the FDA for 510K clearance.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0105 USD | +5.00% | +9.38% | -32.26% |
Apr. 16 | REMSleep Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | REMSleep Holdings, Inc. cancelled the transaction announced on September 18, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-32.26% | 15.35M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- RMSL Stock
- News REMSleep Holdings, Inc.
- Remsleep Holdings Inc. Announces Completion of Deltawave Cpap Mask